CYTARABINE + Azacitidine + Venetoclax for pyloric stenosis, hypertrophic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Apr 2025: Trial started, NCT07012447
  2. 10 Jun 2025: Trial registered, NCT07012447

The trials

NCT07012447: Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

State
Under way
Phase
Phase 2
People
32 planned
Started
1 Apr 2025
Primary completion
1 Apr 2027
Arms
Investigational ( venetoclax, azacytidine)
Results
None posted
  1. 1 Apr 2025: Trial started
  2. 10 Jun 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.